Deucravacitinib maintains efficacy through 2 years in psoriasis
Click Here to Manage Email Alerts
MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress.
“Many of the drugs we use lose efficacy over time, but we now have 2-year data of deucravacitinib, and it is a completely flat line. Patients who did well continue to do just as well 2 years later,” Mark G. Lebwohl, MD, professor of dermatology at the Icahn School of Medicine at Mount Sinai, told Healio.
This 112-week long-term extension trial included 265 patients from the global phase 3 POETYK PSO-1 trial who received continuous deucravacitinib 6 mg daily, a tyronise kinase 2 (TYK2) inhibitor, from day 1, of which 173 achieved PASI 75 at week 16.
Overall response rates were consistent from weeks 52 to 112 with modified nonresponder imputation response rates of 82.4% for PASI 75, 55.2% for PASI 90 and 66.5% for sPGA of 0/1.
In patients who achieved PASI 75 by week 16 and continued treatment, 90.1% maintained PASI 75 through week 52 and 91% did so through week 112. PASI 90 had been achieved by 62.6% of this population by week 16 and at weeks 52 and 112 it was maintained by 64.9% and 63%, respectively.
“Right now, we have a large number of drugs for psoriasis. Most of them are injectable biologics,” Lebwohl said. “We finally have a drug that has a degree of efficacy that matches biologics, so that’s a huge change for dermatology.”